Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu

   Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season
                          Boosts Numbers for Tamiflu

PR Newswire

NEW YORK, May 6, 2013

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical
drug resource, today released first quarter 2013 U.S. prescription sales data
for the top 100 drugs.

(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )
(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b )

The top five drugs have minor shifts in rank but exhibit positive growth for
Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium,
AstraZeneca's leading acid blocker, rank as the top two drugs by sales for the
fourth quarter in a row. Both agents hover in the $1.5 billion range for
quarterly sales.

Top Five Drugs by Sales, Q1 2013

Drug Name     Sales ($000) % Change

                         (previous quarter)
Abilify       $1,526,228   3.24%
Nexium        $1,458,964   1.21%
Cymbalta      $1,296,843   5.65%
Crestor       $1,295,760   1.59%
Advair Diskus $1,277,171   6.00%

Cymbalta, Eli Lilly's heavily promoted depression and pain agent, moves past
Crestor, AstraZeneca's leading statin, even as Cymbalta faces end-of-year
patent loss. Advair Diskus, GlaxoSmithKline's cornerstone asthma and COPD
inhaler, grabs the fifth spot.

Top Five Sales Gains, Q1 2013

Drug Name Gain ($000) % Change

                    (previous quarter)
Tamiflu   $155,019    +65.38%
Synagis   $130,943    +46.47%
Advair    $72,298     +6.00%
Cymbalta  $69,359     +5.65%
Diovan    $63,538     +13.39%

The most recent U.S. influenza season hit long and hard. Roche's Tamiflu jumps
32 spots and posts a 65 percent sales increase. Other respiratory medications,
including Synagis for pediatric respiratory syncytial virus and the
aforementioned Advair, also saw a boost in sales gains.

"Seasonal fluctuations in pharmaceutical sales are common, particularly in
cold, flu and allergy seasons," said Philip Thornton, CEO of Drugs.com. "This
year's flu activity, which started about four weeks early and was relatively
severe, is evident in the Tamiflu numbers."

Top Five Sales Losses, Q1 2013

Drug Name  Loss ($000) % Change

                     (previous quarter)
modafinil  -$46,169    -17.44%
Avonex     -$33,647    -9.05%
Incivek    -$32,155    -12.08%
enoxaparin -$29,058    -7.37%
Truvada    -$28,924    -5.11%

The drugs with the top five dollar losses for the quarter each forfeit between
$28 and $46 million. Avonex and Incivek make repeat appearances from last

Modafinil, the generic version of Teva's Provigil used to improve wakefulness,
was launched in Q2 2012 but sales have since slowed. Sales of Biogen Idec's
Avonex continue to slide in response to the approval of oral multiple
sclerosis drugs, which might include their own Tecfidera. Incivek sales also
dropped -- new Hepatitis C approvals are in the wings, and a serious skin
reaction resulted in a newly penned Box Warning for Incivek.

Detailed data on the top 100 drugs can be accessed at:

About Drugs.com

Drugs.com is the leading online drug information resource with over nine
million unique visitors per month (ComScore, March 2013). Providing free,
independent, peer-reviewed, and up-to-date information at both consumer and
professional levels, Drugs.com empowers patients and caregivers to take charge
of their health and be more informed than ever before. The site includes many
interactive tools and mobile apps to assist consumers, healthcare
professionals and researchers, such as personal medication records, a drug
interaction checker, pill identification wizard, symptom checker, pharma sales
statistics and more.

For more information, visit:http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
(718) 395 2473

This press release was issued through eReleases® Press Release Distribution.
For more information, visit http://www.ereleases.com.

SOURCE Drugs.com

Website: http://www.drugs.com
Contact: Paul Wager, Drugs.com Press Officer, (718) 395 2473
Press spacebar to pause and continue. Press esc to stop.